Logo - springer
Slogan - springer

New & Forthcoming Titles | Cancer Drug Discovery and Development (About the Editor)

Cancer Drug Discovery and Development

Cancer Drug Discovery and Development

Series Ed.: Teicher, Beverly A.

ISSN: 2196-9906

Dr. Beverly A. Teicher, PhD is Chief of the Molecular Pharmacology Branch at NCI, a position that she assumed in early 2011. Dr. Teicher completed a PhD in Bioorganic Chemistry at the Johns Hopkins University and postdoctoral training at Yale University School of Medicine. Dr. Teicher joined Dana-Farber Cancer Institute as an Assistant Professor of Pathology and rose to Associate Professor of Medicine and Radiation Therapy, Harvard Medical School at Dana-Farber Cancer Institute and Joint Center for Radiation Therapy. In 1997, Dr. Teicher was appointed Research Advisor in Cancer Drug Discovery at Lilly Research Laboratories before joining Genzyme Corporation in 2002 where Dr. Teicher was Vice President of Oncology Research for 9 years. Dr. Teicher is best known for her work in solid tumor models and physiologic measurements and the study of drug combinations in vivo with determination of tumor cell kill and bone marrow CFU-GM killing in the same host. Dr. Teicher has headed laboratories and teams that have contributed critical preclinical studies to several approved anticancer agents and several investigational agents currently in clinical trial.

Alerts for this Series

Get the table of contents of every new volume published in Cancer Drug Discovery and Development.